Delivery Order SPE2DB20D9127-SPE2DB25FPRE8
- Not listed
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $7,737.00 by the Defense Logistics Agency (DLA) on September 15, 2025, for the supply of Xolair 150 mg/ml syringes. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of October 6, 2025, and carries no set-aside designation. This award is issued under DMS Pharmaceutical Group's larger single-award...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, has been awarded a delivery order by the Defense Logistics Agency (DLA) for Xolair 150 mg/ml syringes with a ceiling value of $21,276.75. This firm fixed-price delivery order, issued on September 18, 2025, is expected to be completed by October 9, 2025. The award represents a specific procurement action executed under DMS Pharmaceutical Group's larger Indefinite Delivery...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order by the Defense Logistics Agency on September 17, 2025, for Xolair 150 mg/mL syringes, with a ceiling value of $1,547.40. This firm fixed-price delivery order is part of DMS Pharmaceutical Group's larger single-award Indefinite Delivery Contract with the DLA under the SPE2DB program, valued at approximately $500 million and valid through November...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, has been awarded a firm fixed-price delivery order valued at $5,581.44 by the Defense Logistics Agency (DLA) for the supply of Xolair 300 mg/2 ml syringes. The delivery order, issued on September 10, 2025, carries an ultimate completion date of October 1, 2025, with no set-aside designation applied. This award represents a specific task order issued under DMS Pharmaceutical...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $4,642.20 by the Defense Logistics Agency (DLA) on September 4, 2025. The delivery order is for Xolair 150 mg/ml syringes, with an ultimate completion date of September 25, 2025. This award carries no set-aside designation, allowing the vendor to compete on equal footing in the federal procurement marketplace. The place of...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $3,094.80 by the Defense Logistics Agency on August 27, 2025, for the supply of Xolair 150 mg/ml syringes. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of September 18, 2025, and carries no set-aside designation. This award is issued under DMS Pharmaceutical Group's larger single-award...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $1,547.40 by the Defense Logistics Agency (DLA) on September 12, 2025, for the supply of Xolair 150 mg/ml syringes. This firm fixed-price delivery order, with an ultimate completion date of October 3, 2025, is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA under the SPE2DB program, valued at...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order by the Defense Logistics Agency (DLA) on August 14, 2025, for the supply of Xolair 300 mg/2 mL syringes. The contract is valued at $3,720.96 and is structured as a firm fixed-price delivery order with an ultimate completion date of September 5, 2025. This award was made without a set-aside designation, allowing the vendor to compete on the open...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, has been awarded a firm fixed-price delivery order valued at $1,712.22 by the Defense Logistics Agency (DLA) for the supply of Xolair 150 mg/ml auto-injectors. The delivery order, issued on September 12, 2025, with an ultimate completion date of October 3, 2025, carries no set-aside designation. This award is issued under DMS Pharmaceutical Group's larger Indefinite Delivery...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $17,122.20 by the Defense Logistics Agency on August 1, 2025, for the supply of Xolair 150 mg/ml auto-injectors. The award is issued under a firm fixed-price contract structure with an ultimate completion date of August 22, 2025, and represents no set-aside designation. This delivery order draws from DMS Pharmaceutical Group's larger...
- SPE2DB20D9127Indefinite Delivery Contract
- SPE2DB20D9127-SPE2DB25FPRE8Delivery Order
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $37,137.60 by the Defense Logistics Agency (DLA) on August 21, 2025. The delivery order, which carries no set-aside designation, is for Xolair 150 mg/ml syringes with an ultimate completion date of September 12, 2025. This award represents a single delivery order issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA under the SPE2DB program, a $499.999 billion comprehensive pharmaceutical supply agreement valid through November 2026. Xolair (omalizumab) is a monoclonal antibody biologic used primarily for treating moderate-to-severe allergic asthma and chronic idiopathic urticaria. Under its IDC vehicle with DLA, DMS Pharmaceutical Group serves as a critical supplier of pharmaceutical products, including branded and generic prescription medications, biologics, and medical consumables to Department of Defense healthcare facilities worldwide. The company's contract portfolio demonstrates consistent success in federal pharmaceutical procurement, leveraging its small business status to compete effectively while maintaining a robust distribution network supporting military health system requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $37.1k | 8/21/25 |